Neurocrine's crinecerfont meets Phase 3 endpoint in CAH adults; FDA submission planned for 2024

NEUROCRINE BIOSCIENCES INC

Phase 3 CAHtalyst Adult study met primary endpoint: significant % reduction in daily glucocorticoid dose with androgen control (p<0.0001).
Key secondary endpoint met: significant decrease in androstenedione at Week 4 vs placebo (p<0.0001).
63% of crinecerfont patients achieved physiologic glucocorticoid dose vs 18% on placebo (p<0.0001).
Company to submit regulatory applications to FDA in 2024 and to EMA afterwards.
Crinecerfont generally well-tolerated; common AEs: fatigue, headache, coronavirus infection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.